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Clinical Implications In the difficult-to-treat subgroup of patients with chronic
rhinosinusitis with nasal polyps (CRSwNP) and
comorbid aspirin-exacerbated respiratory disease,
dupilumab significantly improved CRSwNP disease
outcomes, along with asthma control and lung function.
This is preliminary evidence of the effect of dupilumab in
patients with CRSwNP and comorbid aspirin-
exacerbated respiratory disease.TO THE EDITOR:
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a
predominantly type 2emediated inflammatory disease associated
with a high symptom burden and poor health-related quality of
life.1 Dupilumab, a fully human VelocImmune-derived2,3 mAb,
blocks the shared receptor component for IL-4 and IL-13, thus
inhibiting signaling of both IL-4 and IL-13, cytokines that are
key drivers of type 2 diseases such as atopic dermatitis (AD),
asthma, allergic rhinitis, and food allergies, which are often
associated as comorbidities. Dupilumab is approved by the
US Food and Drug Administration for the treatment of adults
with moderate-to-severe AD whose disease is inadequately
controlled with topical prescription therapies or for whom those
therapies are not advisable, and can be used with or without
topical corticosteroids, and by the European Medicines Agency
for use in adults with moderate-to-severe AD who are candidates
for systemic therapy. Dupilumab is also approved by the
US Food and Drug Administration as an add-on maintenance
treatment in patients 12 years or older with moderate-to-
severe asthma with an eosinophilic phenotype or with oral
corticosteroidedependent asthma,4 and has demonstrated
positive results in proof-of-concept studies for patients with
eosinophilic esophagitis.5
Bachert et al6 have described a phase 2a dupilumab trial in
patients with CRSwNP refractory to intranasal corticosteroids. In
this proof-of-concept study (ClinicalTrials.gov Identifier:
NCT01920893), dupilumab in conjunction with mometasone
furoate nasal spray significantly improved endoscopic, radio-
graphic, clinical, and patient-reported outcomes in these patients,
many of whom had comorbid conditions. Patients with
CRSwNP with comorbid aspirin-exacerbated respiratory disease
(AERD), also referred to as nonsteroidal anti-inflammatory drug-
exacerbated respiratory disease, are among the most severe and
difficult to treat.7 An estimated 8% to 26% of patients with
CRSwNP are reported to have comorbid AERD.8,9Of the 60 patients with CRSwNP enrolled in the
NCT01920893 study, 19 (31.7%) had self-reported comorbid
AERD (8 in the dupilumab-treated group and 11 in the placebo
group); this included patients reporting sensitivity to aspirin as
well as other nonsteroidal anti-inflammatory drugs. Most
patients reporting AERD were women (57.9%), and there was a
much lower proportion of women in the aspirin-tolerant
subgroup (36.6%). At baseline, the patients with AERD had a
significantly higher mean Lund-Mackay total score than did
patients without AERD (21.2  2.4 vs 17.5  5.8, respectively;
P ¼ .03). In patients with comorbid asthma, mean FEV1 (L) was
lower, although not significantly so, in those with AERD
compared with those who were aspirin-tolerant (2.4  0.6 vs 2.9
 0.9, respectively). Patients with AERD experienced severe loss
of smell at baseline, more so than aspirin-tolerant patients, as
indicated by the higher mean score for the “sense of smell/taste”
question in the 22-item Sino-Nasal Outcome Test (SNOT-22)
and the lower mean score for the University of Pennsylvania
Smell Identification Test in the former group (4.7  0.6 vs 4.2
 1.2 and 11.2  4.9 vs 15.6  9.0, respectively; P ¼ not
significant for both). Baseline data are presented in Table E1 in
this article’s Online Repository at www.jaci-inpractice.org.
Mean baseline nasal polyp score (NPS) was similar among
patients with and without AERD (a score of 5 was required for
participation in the study).6 Dupilumab treatment resulted in a
significant reduction in mean NPS from baseline to week 16 in
the AERD patient subgroup (least-squares mean difference vs
placebo of 2.51). Aspirin-tolerant patients also showed
reductions in NPS (least-squares mean difference vs placebo
of 0.72), but these did not reach statistical significance
(Figure 1, A). At week 16, dupilumab-treated patients in both
the AERD and aspirin-tolerant subgroups experienced significant
improvements in Lund-Mackay total score, SNOT-22 total
score, SNOT-22 sense of smell/taste score, and University of
Pennsylvania Smell Identification Test score, and significant
reductions in daily morning nasal congestion/obstruction score
(Figure 1, B, C, D, E, and F, respectively) compared with
placebo. Dupilumab treatment significantly improved the 5-item
Asthma Control Questionnaire total score in patients with
AERD and comorbid asthma at weeks 12 and 16 vs placebo. In
aspirin-tolerant patients with comorbid asthma, the change from
baseline with dupilumab treatment versus placebo was significant
at weeks 8, 12, and 16 (Figure 2, A and B). In dupilumab-treated
patients with AERD and comorbid asthma, there was a signifi-
cant change from baseline in FEV1 (L) at weeks 8 and 16
(380 mL and 360 mL, respectively) compared with placebo
group patients. Changes were clinically meaningful at all time
points, ranging from 160 mL to 380 mL. Although not signif-
icant, the change from baseline FEV1 (L) in aspirin-tolerant
patients with comorbid asthma, dupilumab versus placebo, was
clinically meaningful at all time points, ranging from 150 mL to
210 mL (statistical nonsignificance was most likely due to the
small sample size) (Figure 2, C and D).
Treatment-emergent adverse events (TEAEs) were similar
among patient subgroups based on the presence/absence of
AERD comorbidity. Of the TEAEs that occurred in more than
10% of either the dupilumab or placebo treatment group,1
FIGURE 1. Disease burden/symptoms at baseline and at week 16 by (A) NPS, (B) LMK total score, (C) SNOT-22 total score, (D) SNOT-22
sense of smell/taste score, (E) UPSIT score, and (F) AM nasal congestion/obstruction score. AM, Morning; LMK, Lund-Mackay; UPSIT,
University of Pennsylvania Smell Identification Test. AERD: placebo n ¼ 11, dupilumab n ¼ 8. Non-AERD: placebo n ¼ 19, dupilumab
n ¼ 22. Non-AERD represents aspirin-tolerant patients. In Figure 1, A, range of 0 to 8; higher scores indicate worse polyp burden. In
Figure 1, B, range of 0 to 24; higher scores indicate more opacification. In Figure 1, C, range of 0 to 110; higher scores indicate poorer
outcomes, and differences greater or equal to 8.9 are considered clinically meaningful. In Figure 1, D, range of 0 to 5; higher scores
indicate worse sense of smell. In Figure 1, E, range of 0 to 40; higher scores indicate better sense of smell, scores of 35 to 40 indicate
normal sense of smell. In Figure 1, F, range of 0 to 3; symptoms were captured using a categorical scale (0 ¼ no symptoms, 1 ¼ mild,
2 ¼ moderate, 3 ¼ severe). *P < .05, **P < .005, ***P < .0005. P value represents change from baseline, dupilumab vs placebo.
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FIGURE 2. Asthma-related outcomes, including ACQ-5 score (A) at baseline and at week 16 and (B) by visit, and (C) FEV1 (L) at baseline
and at week 16 and (D) by visit for AERD patient subgroups with comorbid asthma. ACQ-5, 5-Item Asthma Control Questionnaire; NS,
not significant. AERD with asthma: placebo n ¼ 10, dupilumab n ¼ 7. Non-AERD with asthma: placebo n ¼ 9, dupilumab n ¼ 9.
Non-AERD represents aspirin-tolerant patients. ACQ-5 score: Range of 0 to 6; lower scores indicate better asthma control, and differ-
ences greater than or equal to 0.5 are considered clinically meaningful. *P < .05, **P < .005. P value represents change from baseline,
dupilumab vs placebo.
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CLINICAL COMMUNICATIONS 3epistaxis (reported by 8 aspirin-tolerant patients; 1 patient with
AERD), oropharyngeal pain (experienced by 8 aspirin-tolerant
patients; 1 patient with AERD), and bronchitis (occurring in
5 aspirin-tolerant patients and in 0 patient with AERD) were
more common in aspirin-tolerant patients than in those with
AERD. TEAEs for the intent-to-treat population have been
described previously by Bachert et al.6
In summary, patients with AERD had greater sinus opacifi-
cation and worse sense of smell (a symptom typically associated
with CRSwNP, particularly in those with comorbid AERD) at
baseline compared with aspirin-tolerant patients with CRSwNP,
and patients with CRSwNP with comorbid asthma and AERD
had poorer lung function at baseline than did patients with
CRSwNP with asthma without AERD. These baseline results
indicate more severe disease in patients with AERD. Dupilumab
significantly improved CRSwNP disease outcomes, in addition
to improving asthma control and lung function, in the studypopulation and, in particular, in the difficult-to-treat subgroup of
patients with CRSwNP with comorbid AERD. Although larger
studies are needed to confirm efficacy, this is preliminary
evidence of the effect of dupilumab in a small number of patients
with CRSwNP and comorbid AERD.Acknowledgments
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CLINICAL COMMUNICATIONS 4.e1ONLINE REPOSITORYTABLE E1. Baseline demographic and clinical characteristics
Characteristic AERD (n [ 19) Non-AERD (n [ 41)
P value AERD
vs non-AERD
Age (y), mean  SD 50.5  5.4 47.4  10.7 NS
Sex: female, n (%) 11 (57.9) 15 (36.6) NS
Nasal polyposis duration (y), mean  SD 10.6  8.0 9.0  7.6 NS
Patients with comorbid asthma, n (%) 17 (89.5) 18 (43.9) .001
Disease burden/symptoms
Endoscopic NPS, mean  SD 5.7  1.0 5.8  1.0 NS
CT scan LMK total score, mean  SD 21.2  2.4 17.5  5.8 .026
SNOT-22 score, mean  SD 41.3  18.7 40.9  19.3 NS
SNOT-22 sense of smell/taste score, mean  SD 4.7  0.6 4.2  1.2 NS
UPSIT, mean  SD 11.2  4.9 15.6  9.0 .050
AM symptom score for nasal congestion/obstruction, mean  SD 1.6  0.7 1.7  0.7 NS
Asthma-related symptoms n [ 17 n [ 18
ACQ-5 score, mean  SD 1.4  0.9 1.8  1.0 NS
FEV1 (L), mean  SD 2.4  0.6 2.9  0.9 NS
ACQ-5, 5-Item Asthma Control Questionnaire; AM, morning; CT, computed tomography; LMK, Lund-Mackay; NS, not significant; UPSIT, University of Pennsylvania Smell
Identification Test.
